Navigation Links
Clarient's Board of Directors Recommends Stockholders Accept General Electric's Cash Tender Offer
Date:11/5/2010

the proposed transaction, Clarient's ability to continue to develop and expand its diagnostic services business, uncertainties inherent in Clarient's product development programs, Clarient's ability to attract and retain highly qualified managerial, technical, and sales and marketing personnel, Clarient's ability to maintain compliance with financial and other covenants under its credit facility, Clarient's ability to successfully manage its in-house billing and collections processes, the continuation of favorable third-party payor reimbursement for laboratory tests, changes in federal payor regulations or policies, including adjustments to Medicare reimbursement rates, that may affect coverage and reimbursement for Clarient's laboratory diagnostics services, Clarient's ability to obtain additional financing on acceptable terms or at all, unanticipated expenses or liabilities or other adverse events affecting cash flow, uncertainty of success in identifying, developing and commercializing new diagnostic tests or novel markers including the Mammostrat(R) test, Clarient's ability to fund development of new diagnostic tests and novel markers, and to obtain adequate patent protection covering Clarient's use of these tests and markers including for the Mammostrat(R) test, and the amount of resources Clarient determines to apply to novel marker development and commercialization, the risk to Clarient of infringement claims and the possibility of the need to license intellectual property from third parties to avoid or settle such claims, failure to obtain regulatory approvals and clearances required to conduct clinical trials if/when required and/or to commercialize Clarient's services and underlying diagnostic applications, Clarient's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in Clarient's SEC reports, in
'/>"/>
SOURCE Clarient, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
3. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
4. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
5. Regenesis Biomedical Announces Additions to Board of Directors
6. GM Exec Joins Bio-Reaction Industries Board of Directors
7. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
8. SulphCo Adds New Board Member
9. Landauer, Inc. Appoints Two New Members to Board of Directors
10. Resverlogix Board of Directors Update
11. MedQuist Announces Additions to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014 /PRNewswire/ ... announced today that Medtronic, Inc. (NYSE: ... to the U.S. Food and Drug Administration (FDA) ... II implantable drug infusion system (including a newly ... ® (treprostinil) Injection delivered intravenously to patients ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ... revenue and share analysis. , Full Copy ...
(Date:12/24/2014)... 23, 2014 Earlier this year in ... Sherley, director of the Adult Stem Cell Technology Center, ... overlooked and under appreciated unique property of adult tissue ... Stem Cells: Misunderstood in the Past, Important for the ... participants. He gave the address at the 4th ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... that it has signed an asset purchase agreement to ... Bulletin,Board: IMMC) for $31 million in cash subject to ... certain claims owing to,Veridex, LLC and the assumption of ... include intellectual property, product,inventory and clinical data as well ...
... announced the launch,of the WellCentive Secure Messaging ... its,popular online patient registry system for health ... ) provides a web-based,preventive care and chronic ... health insurance companies and other,health care organizations. ...
... leading,provider of screening solutions for drug discovery, today ... agreement Cellectricon,will provide AstraZeneca with two of its ... screening., Cellectricon and AstraZeneca formed and announced ... solution to major bottlenecks in ligand gated ion,channel ...
Cached Biology Technology:Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation 2WellCentive Launches New Secure Messaging Platform for Its Patient Registry System 2WellCentive Launches New Secure Messaging Platform for Its Patient Registry System 3Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology 2
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ... "Global Chemical Sensor Market 2015-2019" report to ... One major trend upcoming in ... sensors in biomedical applications. Chemical sensors help in ... diagnosis during surgical procedures. The Global Chemical Sensor ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Based on a pilot study in children with sarcoma, ... that immunotherapy could prove beneficial in treating high-risk forms ... novel dendritic vaccine as well as a standard flu ... Their findings, published in the August 1 issue ...
... surprisingly simple, inexpensive technique, chemists have found a way ... amounts of electricity, common chemicals and a room-temperature glass ... fuels, many researchers have proposed using solar electricity to ... when the sun goes down. One of the chief ...
... NY In the United States, Lyme disease is ... from animals to humans. These animal-borne diseases can make ... and effective intervention are crucial to protecting the public. ... Millbrook, NY recently received $750,000 in grant funding from ...
Cached Biology News:Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3Water refineries? 2Water refineries? 3EPA funds ground-breaking Lyme disease research 2
... Invitrogen makes blotting of E-PAGE Gels ... pre-cut fiber blotting pad and several types ... perfectly fit 8.6 cm x 13.5 cm ... PVDF membranes are designed for western transfer ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... the basic components and protocol required ... plates for quantitation of a specific ... culture supernate. Every Screening Set contains ... (5 individual standards), Streptavidin-HRP, TMB Substrate ...
Biology Products: